ESMO 2024

New updates from the innovative I-SPY program

Escalation, De-escalation and management of therapy: how to identify the best treatment option for our patients?

4-year update of Riboclib in EBC - can we avoid chemo?

Hypofractionation in early breast cancer

Therapy de-escalation and balancing individualized therapy management in early breast cancer patients

Survival data from WSG-TP-II

Endocrine therapy in triple-positive premenopausal patients

Physical exercise and oncological outcome

Registry data from France - no break in endocrine therapy in young patients

Compliance is everything

Survival benefit reported with Pembro

Overall survival advantage for Pembrolizumab in early TNBC

Ribociclib in younger patients

Evaluation of the patient collective under 40 years

4-year landmark data

Update on NATALEE in young patients

Physical exercise and oncological outcome

Update on NATALEE in young patients

T-DXD for everyone - what is the minimal threshold for HER2: How to sequence therapies?

De-Escalation in the metastatic setting

No benefit of Akt-inhibition in mTNBC

Keep the patients trained!

New approaches to treat 1L patients mTNBC

Brain imaging screening in MBC patients

Brain imaging screening in MBC patients

Akt-inhibition works with HR+ but not with mTNBC

TILs and overall survival in the shortHER trial

Highlights of ESMO 2024

PIK3CA is not a vaild pathway in triple-negative breast cancer

TILs e sopravvivenza nello studio shortHER

PIK3CA is not a vaild pathway in triple-negative breast cancer

Punti salienti di ESMO 2024

Nuovi approcci per il trattamento dei pazienti 1L mTNBC

New first choice treatment for patients with brain metastases?

Promosing results for the new ADC in HR+ - negative results for pAKT inhibitors in mTNBC: we have to better understand the biology.

T-Dxd in patients with and without brain metastases

Endocrine-based therapy in combination with dual blockade

Soon no chemotherapy for triplenegative mBC

Outstanding efficacy of T-Dxd in CNS meastases

HER3- DXd in the ICARUS Breast-01 study

Her3-Dxd - new application area for ADCs

High sensitivity testing as outcome predictor for T-DXD in mBC

ctDNA data and clinical efficacy of SG

Primary results of DB-12

T-Dxd in BrainMets

Primary systematic treatment of active brain metastases

Optimization treatment with ADCs in endocrine therapy

Efficacy of T-Dxd in patients with brain metastasis

Study impression in HR+/HER2- mBC progressing after two lines of therapy

Impression d'étude dans le cancer du sein métastatique HR+/HER2- progressant après deux lignes de traitement

Optimization treatment with ADCs in endocrine therapy

Risultati primari dello studio DB-12

Impressione dello studio nel carcinoma mammario metastatico HR+/HER2- in progressione dopo due linee di terapia

Endocrine resistance to CDK4/6 inhibitors

Screening for brain metastases – what do doctors and patients think about it?

CTCs as surrogate markers for endocrine therapy

Niraparib in ovarian cancer without survival benefit

Overview on the perioperative treatment landscape

The importance of markers for patient management

Negative adjuvant CPI trial

Neoadjuvant vs. Perioperative

Significant CNS protection by osimertinib

ctDNA - a promising new biomarker in early lung cancer

Getting rid of it will save your life!

Durvalumab did not meet primary endpoint in CCTG BR.31 trial

Perioperative IO Therapy - adjuvant necessary?

Should we move away from adjuvant immunotherapy?

BR31: The first negative adjuvant study in resected NSCLC

BR31: La première étude d’immunothérapie adjuvante négative dans les CBNPC réséqués

Should we move away from adjuvant immunotherapy?

Durvalumab non ha raggiunto l'endpoint primario nello studio CCTG BR.31

Eliminarlo potrebbe salvarti la vita

Update on genetic alterations - ALK / ROS / KRAS / BRAF

Pieces of evidence in the EGFR domain

New 1st line treatment opportunities in advanced stage NSCLC

Adding anti-LAG-3 doesn't seem to being worth it

The next generation of ALK inhibitors

Half of the dose - same activity: provocative findings from NVALT-30

Sustained OS at 2nd interim analysis in MARIPOSA-2

Optimizing the dose of immunotherapy

NVL-655: a promising new ALK inhibitor

Promising signal for anti-TIGIT + anti-PD-1 with PD-L1 > 50 %

The next generation of ROS inhibitors

4th generation with ALK-alterations

Bispecific antibodies better than ADCs?

RELATIVITY-104: efficacy of anti immunotherapy

Two sometimes may be better than one!

Early mechanisms of resistance from MARIPOSA

Patterns of resistance in MARIPOSA trial

Survival Data with Amivantamab for EGFR Alteration

MARIPOSA - lower rate of MET amplification and EGFR resistance mutation

Second interim analysis of MARIPOSA-2

1st line encorafenib + binimetinib: combination is very active but PFS very different

NVL-520 for ROS alteration - already best in class?

NVALT: 1st attempt to reduce dose of pembrolizumab and limit the financial burden

Quality of life with Telisotuzumab in LUMINOSITY

Quality of life with Telisotuzumab in LUMINOSITY

Patterns of resistance in MARIPOSA trial

Aggiungere l'anti-LAG-3 non sembra valerne la pena

Second interim analysis of MARIPOSA-2

2 a volte sono meglio di uno

NVALT: Première tentative pour réduire la dose de pembrolizumab dans les CBNPC de stade IV et réduire le cout du traitement

Optimizing the dose of immunotherapy

RELATIVITY-104: efficacy of anti immunotherapy

CBNPC muté BRAF en 1ère ligne : encorafenib + binimetinib : association très active mais la SSP très différente selon les études

New data on SCLC and mesothelioma

Subset analysis from ADRIATIC

New standard of care in LS-SCLC

Neuer Behandlungsstandard beim LS-SCLC

Response assessment in mesothelioma - can AI help?

Is the radiologist redundant in mesothelioma RECIST measurements

Is the radiologist redundant in mesothelioma RECIST measurements

IO in mCRPC: Let's move on to the next substance?!

Doublet therapy in prostate cancer: Practice changing or rather practice informing?

Practice changing- Big Revival - Or just a Splish? Don't forget the bone protection!

Molecular analysis from PEACE-1

Was it a splash or was it a splish?

Metformin in mHSPC

PSMA-radioligand - the first study of its kind

Radium223 Prior to Docetaxel Improves Quality of Life in Bone-Dominant mCRPC: Findings from the RAPSON Phase 2 Trial

Not a Patch on ADT?

We come in PEACE

Radium-223 an option again?

Radium and enzalutamide in mCRPC - final results

New PSMA-ligand

LuPSMA moves UpFront

Upfronts in personal

New hormone therapy for mCRPC

Did CONTACT make any contact?

Darolutamide in mHSPC

Immunotherapy for prostate cancer

Radium and enzalutamide in mCRPC - final results

Molecular analysis from PEACE-1

PSMA-radioligand - the first study of its kind

New PSMA-ligand

Where is the right place for HIF inhibitors in advanced RCC therapy?

IO after IO – is there a role for sequential immunotherapy in RCC?

Microbiome transplantation in RCC – how to tailor this therapy for our patients

Establishing ICI as standard of care in RCC

New SOC for non-cc-RCC?

IO therapy is standard for nccRCC

SUNNIFORECAST - rain or shine?

The role of sequencing therapy in RCC

Glycoproteins as Predictive Biomarkers for Nivolumab Plus Cabozantinib Response in Advanced Renal Cell Carcinoma

FMT in a novel setting

Stool transplantation is the shit

Treating nccRCC - Nivo/Ipi as a new potential option

Ipi-Nivo in nccRCC

My view on SUNNIFORECAST

HIF-2a inhibitors are on their way

Opening a new way of treatment in MIBC

Immunotherapy for nccRCC

Sequencing checkpoint inhibitors - the story is over

CPI - modification / prediction - fact or fantasy?

Updated survival results

TKI monotherapy remains standard in 2ndL

mRCC ≥ 1L? News on intensification?

Sequencing checkpoint inhibitors - the story is over

Tratamiento del nccRCC - Nivo/Ipi como nueva opción potencial

Se abre una nueva vía de tratamiento en el cáncer de vejiga con invasión muscular

Chemo + IO in the perioperative setting - new standard of care

Encouraging data - but we need more data!

Biomarkers in Bladder cancer - the road to individualized therapy

Value of ctDNA

New standard: perioperative MIBC-NIAGARA

New data on ADCs in bladder cancer

mUC - new ADC's?

Practice changing new data in Bladder cancer at ESMO24

Pretzel therapy for superficial UC

EV + Pembro is broadly effective

TAR200 intravesical +/- Cetrelimab in HR (N)MIBC

A new way to give chemo for patients who are ineligible for neoadj therapy

NIAGARA sets new standard

Is intravesical therapy as easy as baking a pretzel?

Nivolumab Plus Gemcitabine-Cisplatin Maintains Quality of Life in Metastatic Urothelial Carcinoma

Nuevos datos sobre las ADC en el cáncer de vejiga

Practice changing new data in Bladder cancer at ESMO24

A new way to give chemo for patients who are ineligible for neoadj therapy